Is the medicine for treating hepatitis B useful?

How to choose drugs for treating hepatitis B

[] clicks: font: large, medium and small

-

At present, there are many drugs and treatments for chronic viral hepatitis in advertisements. The key is how to judge which treatments are effective and how to choose these drugs. I only talk about my personal views for your reference.

First, there is no official approval number of the Ministry of Health. If it is the quasi-trade name of Wei medicine, it is a reliable drug that has been clinically verified. If it is a health care product, it may not be effective for treatment.

Second, whether there are clinical verification data. If not, you can ask the pharmaceutical factory for it. Pay attention to the following points after obtaining clinical verification data:

1。 Are these verification units trusted by you or doctors you are familiar with? Because clinical verification is a very rigorous science, a little carelessness will lead to wrong conclusions. I have encountered several drugs, and it has been preliminarily verified that the negative conversion rate of HBsAg can reach over 60%. At that time, some newspapers also publicized it with great fanfare for some time. But the result is completely invalid. I don't think this can be attributed to newspapers or pharmaceutical companies, nor can it be considered that the verification unit deliberately falsifies, which is probably an illusion caused by lax testing. In our own research, we also encountered a report that a drug made all hepatitis B virus nucleic acids (HBV-DNA) negative. Fortunately, the patient fluid I sent for inspection at that time contained both pre-treatment samples and post-treatment samples. Both the treatment group and the control group have it, and it is impossible to turn all negative. After careful inspection, it was found that it was a problem with the detection reagent. Therefore, for the results of clinical verification, we must see whether it is done by the unit you believe. If so, it is best to try to ask these verification units and doctors if the results are reliable.

A comrade told me that she had participated in a free clinic organized by a pharmaceutical factory. As a result, the pharmaceutical factory took her photo and the big slogan at that time, as if she believed in the medicine. In fact, she knows nothing about this medicine. Free clinic is to treat patients with any medicine, which is not necessarily the medicine of this factory. Therefore, for a "verifier" with a name, it is best to try to ask if this is true.

2。 We should look at the scientific nature of these verification materials. Of course, this is mainly the doctor's judgment, but the patient can also make a preliminary judgment: ① Whether there are enough cases. Whether the treatment of chronic hepatitis is effective or not requires at least 30 pairs of cases, that is, more than 60 cases. If only a few cases, a dozen cases or even one case are reported, the results are not very reliable. ② Whether there is a control group. ③ Whether the patients in the two groups (treatment group and control group) are comparable. For example, whether the male-female ratio, severity of illness, age, course of disease, virus markers, liver function and mother-to-child transmission ratio of the two groups are basically the same, and whether they are carried out in the same period, the same unit (or the same research institution). Because these are all factors that can affect the efficacy of drugs. If it can be "double-blind", the samples before and after treatment can be tested in the same laboratory with the same batch of reagents, and the reliability will be even greater.

Basic materials should also be carefully analyzed. Many data have proved that a drug has antiviral or antitumor effects in vitro (such as tissue culture) or in vivo (such as duck hepatitis and woodchuck hepatitis). This material can only be used as reference or evidence for clinical application, and it cannot be considered that the drug will be effective for human hepatitis and tumor. This is because in vitro (cell) and in vivo (animal) experimental results are not necessarily consistent with the human body. In addition, in vitro experiments, the possibility of clinical application is often ignored. In vitro (22 15 cell line), we screened the anti-hepatitis B virus effects of some Chinese herbal medicines, but in fact, it is difficult to reach the in vitro experimental concentration in vivo, so its clinical application is not so effective.

Third, for clinicians, it is best to treat some patients personally with drugs that you think may be effective (it is best to organize by the leadership of the unit, and every new drug that enters the hospital, especially drugs with unrecognized efficacy, will organize forces to treat some patients), and the number does not need to be too large, 10-20 cases. If the instructions indicate that the negative conversion rate of E antigen and/or HBV—DNA is about 40%, then at least 2-3-4-5 patients in 10-20 patients should be effective. If none of the drugs can prove ineffective, then the negative conversion rate is above 10% and the negative conversion rate is above 40%, which is worth expanding the experiment. In this way, doctors can learn about every new drug.

4. Up to now, there are no drugs and treatments that can really turn hepatitis B surface antigen (anti-Australian, HB-SAG) negative. The best treatment method generally has a negative conversion rate of about 10%, and almost none of them exceed 20%. Therefore, most doctors, drugs or therapies who claim that all or most of HBsAg (> 50%) can be turned negative lack scientific basis and are unreliable. If there is such treatment, we are willing to verify it. As for those materials that claim to make all hepatitis B markers negative, it is even less credible, because hepatitis B markers also include antibodies against surface antigens (anti-HBS), which is a protective antibody. Positive often means that people are immune to hepatitis B virus, so there is no harm in making anti-HBS negative. Even less credible are those who claim to be able to completely cure all kinds of hepatitis, liver cirrhosis and liver cancer.

In a word, don't just watch or listen to how good the propaganda is, but must produce concrete materials and evidence.

However, it must also be pointed out that the natural negative conversion rate of hepatitis B surface antigen in real acute hepatitis B (negative conversion without medication) is very high, almost reaching 100%. If we treat these patients with drugs, we can definitely get a high negative rate of HBsAg. In addition, chronic hepatitis B surface antigen naturally turns negative, generally about 1%-2% every year, so in some cases, hepatitis B surface antigen does turn negative after taking medicine, and it is not certain that the drug will be effective. As for the inaccurate reagent, there will be more false negative results.

Antiviral treatment of chronic hepatitis B is of course very important. Other treatments should be used simultaneously, such as eliminating liver inflammation and reducing or preventing liver fibrosis. No matter what the advertisement says, such as improving immunity and improving liver microcirculation, we should not believe it easily. Be sure to see if there is a reliable basis, and it is best to treat chronic diseases.

The foundation of hepatitis patients.

Phyllanthus urinaria, also known as Phyllanthus urinaria, is an annual or perennial herb with the functions of clearing liver, improving eyesight, dredging meridians and detoxifying. Lysimachia is a citrus plant belonging to Euphorbiaceae, and there are about 600 species of citrus plants in the world. The curative effect of Lysimachia christinae on hepatitis B was discovered by Dr. Zheng Taihao, director of the Hepatitis Research Center established by the World Health Organization in Daegu, South Korea, and the curative effect has been clinically confirmed.

Phyllanthus urinaria is a traditional Chinese medicine prescription recorded in ancient books. According to the records in Supplement to Compendium of Materia Medica, Phyllanthus urinaria is effective in treating various diseases of children, as well as emaciation and blindness. Eupatorium odoratum has been used to protect and treat liver diseases for hundreds of years, and there are many records in Chinese and foreign literature.

During the period of 1980, Dr. Zheng Taihao studied the treatment characteristics of Korean herbs for hepatitis B for many years, and soon he focused on Korean Lysimachia christinae, and found that Korean Lysimachia christinae had been used to treat liver diseases in Korea for centuries, and it was also used as a historical record of eating vegetables. Then he started a series of toxicological experiments and animal experiments, which proved that Lysimachia christinae was harmless to human body, and it was soon proved to be an in vitro study of anti-HBV.

From traditional experience, we know that weeding is safe for people to eat. 199 1 year, Dr. Zheng began to treat patients with chronic hepatitis B, and determined the antiviral characteristics of Lysimachia christinae, because it reduced the content of HBV-DNA (hepatitis virus DNA) in blood.

From 65438 to 0994, Dr. Zheng began to cooperate with doctors from Cornell University in the United States. In the United States, Dr. Zheng's research team commissioned a woodchuck to conduct antiviral research on Lysimachia christinae (the woodchuck's liver is recognized as the animal model closest to the human liver and is most suitable for studying hepatitis B). The results are quite encouraging, which also makes Jubilee of Korea decide to further formally conduct toxicity research and further clinical evaluation in Korea.

Shortly after the establishment of Korea Jinxi Company, 30 human experiments of chronic hepatitis B patients were completed in the laboratory. Dr. Zheng's early research work on Eupatorium odoratum and the results of this experiment were the subject of a paper published in Kyung Pook University Medical Journal, which was presented at the World Health Organization meeting on "Prevention and Control of Viral Hepatitis" held in Tokyo on February 3, and was accepted by the authorities.

Phyllanthus urinaria, Chinese rose. Also known as Phyllanthus urinaria, Phyllanthus urinaria belongs to panicum miliaceum of Euphorbiaceae. It is about 10-40 cm high, with alternate leaves, like compound leaves, and unisexual flowers in the axils. Small fruits are arranged under the leaves, hence the name. In Shan Ye, a suburb of Taiwan Province Province, there are many open spaces.

Eupatorium odoratum is a widely used folk herb, which is used to treat malnutrition, enteritis and hepatitis in children. Hepatitis B is considered as a highly contagious malignant disease, and the incidence of liver cirrhosis and liver cancer is very high. South Korea's World Health Organization (WHO) Hepatitis Control and Treatment Center has spared no effort in hepatitis research. Dr. Zheng Taihao, the person in charge, has selected some special varieties from more than 500 kinds of road yellow. After long-term experiments, it has been proved that it is effective in treating hepatitis B and has no toxicity, so it was introduced to China. Therefore, it is really surprising that this plant that looks like a weed has made great contributions with a small soldier. Although it is not toxic, it is cold, and for some people, it is not suitable for taking it in large quantities or for a long time.

For hepatitis, prevention is more important than treatment, pay attention to hygiene and avoid unnecessary contact with blood and body fluids.